Expression of PiT1 and PiT2 retroviral receptors and transduction efficiency of tumor cells*.

• Authors: Piotr Grabarczyk , Piotr J Wysocki , Katarzyna Gryska , Andrzej Mackiewicz
• Languages of publication: EN

Abstracts

EN

Recombinant retroviral vectors are still the most common gene delivery vehicles for gene therapy purposes, especially for construction of genetically modified tumor vaccines (GMTV). However, these vehicles are characterized by relatively low titre and in the case of many tumor cell lines, low transduction efficiency. We constructed bicistronic retroviral vector pseudotypes of amphotropic murine leukemia virus (A-MuLV) and gibbon ape leukemia virus (GaLV), encoding enhanced green fluorescent protein (EGFP) as a rapid and easily detectable reporter gene. Transduction of five different human melanoma and four renal carcinoma cell lines by these two virus pseudotypes revealed differences in transduction efficiency, which wase markedly lower for the renal carcinoma cell lines. Stimulation of retroviral receptor expression (PiT1 and PiT2) by phosphate depletion induced a limited increase of receptor mRNA levels, but did not improve the gene transfer efficiency. In contrast, simultaneous transduction with both vector pseudotypes markedly increased the transduction efficiency, compared to GaLV or A-MuLV alone. The same effect could be achieved by several repeated exposures of target cells to fresh vector preparation. Overexpression of GaLV receptor (PiT1) in target cells significantly increased the transduction rate and enabled retrovirus mediated gene transfer into the cells which normally are not transducible by GaLV pseudotypes. We demonstrated that, using different transduction strategies, the relatively inefficient, widely used retroviral vector systems could be significantly improved.

Keywords

EN

renal carcinoma; retroviral vectors; PiT1 and PiT2 retroviral receptors; human melanoma

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2002
• Volume: 49
• Issue: 2
• Pages: 333-339

Dates

published

2002

received

2002-04-22

revised

2002-05-30

accepted

2002-06-3

Contributors

author

Piotr Grabarczyk

• Department of Cancer Immunology, Chair of Oncology, K. Marcinkowski University of Medical Sciences, GreatPoland Cancer Center, Poznań, Poland

author

Piotr J Wysocki

• Department of Cancer Immunology, Chair of Oncology, K. Marcinkowski University of Medical Sciences, GreatPoland Cancer Center, Poznań, Poland

author

Katarzyna Gryska

• Department of Cancer Immunology, Chair of Oncology, K. Marcinkowski University of Medical Sciences, GreatPoland Cancer Center, Poznań, Poland

author

Andrzej Mackiewicz

• Department of Cancer Immunology, Chair of Oncology, K. Marcinkowski University of Medical Sciences, GreatPoland Cancer Center, Poznań, Poland

References

• Engelstadter M, Buchholz CJ, Bobkova M. (2001) Targeted gene transfer to lymphocytes using murine leukaemia virus vectors pseudotyped with spleen necrosis virus envelope proteins. Gene Ther.; 8: 1202-6.
• Grabarczyk P, Gryska K, Wysocki PJ, Mackiewicz A. (2001) Improving the retroviral vector (RV) systems for immunotherapy of cancer. Adv Exp Med Biol.; 495: 389-92.
• Hennemann B, Oh IH, Chuo JY, Kalberer CP, Schley PD, Rose-John S, Humphries RK, Eaves CJ. (2000) Efficient retrovirus-mediated gene transfer to transplantable human bone marrow cells in the absence of fibronectine. Blood.; 96(7): 2432-9.
• Kavanaugh MP, Miller DG, Zhang W, Law W, Kozak SL, Kabat D, Miller D. (1994) Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci U S A.; 91: 7071-5.
• Kurre P, Kiem HP, Morris J, Heyward S, Battini JL, Miller AD. (1999) Efficient transduction by an amphotropic retrovirus vector is dependent on high-level expression of the cell surface virus receptor. J Virol.; 73: 495-500.
• Logg CR, Tai CK, Logg A, Anderson WF, Kasahara N. (2001) A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum Gene Ther.; 12: 921-32.
• Morgan JR, LeDoux JM, Snow RG, Tompkins RG, Yarmush ML. (1995) Retrovirus infection: effect of time and target cell number. J Virol.; 69: 6994-7000.
• Pizzato M, Merten OW, Blair ED, Takeuchi Y. (2001) Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors. Gene Ther.; 8: 737-45.
• Uckert W, Becker C, Gladow M, Klein D, Kammertoens T, Pedersen L, Blankenstein T. (2000) Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype. Hum Gene Ther.; 11: 1005-14.
• Yamaguchi S, Wakimoto H, Yoshida Y, Kanegae Y, Saito I, Aoyagi M, Hirakawa K, Amagasa T, Hamada H. (1995) Enhancement of retrovirus-mediated gene transduction efficiency by transient overexpression of amphotropic receptor, GLVR-2. Nucleic Acids Res.; 23: 2080-1.